Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

フッ化ピリミジン系薬剤とプラチナ系薬剤との併用療法に不応となった進行・再発食道癌に対するドセタキセル単独療法とパクリタキセル単独療法のランダム化比較第Ⅱ相試験（OGSG1201）

Stage II/III大腸癌根治切除後の補助化学療法中または治療後に再発したRAS野生型かつBRAF V600E変異型の早期再発大腸癌患者に対するエンコラフェニブ+ビニメチニブ+セツキシマブ療法の有効性と安全性を探索する第II相試験 (TRESBIEN/OGSG2101)

A phase II study of S‑1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)

Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy　(OGSG1201)

Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy（OGSG1201）

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy (OGSG1201)

A phase II trial of ramucirumab plus irinotecan for patients with early relapced gastric cancer